香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 海外監管公告 本公告乃百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條的規定刊發。茲載列本公司於上海證券交易所 網站刊發的《首次公開發行股票科創板上市公告書提示性公告》，僅供參閱。 承董事會命 百奧賽圖（北京）醫藥科技股份有限公司 董事長、首席執行官兼執行董事 沈月雷 香港，2025年12月9日 於本公告日期，本公司董事會包括董事長、首席執行官兼執行董事沈月雷博士、 執行董事倪健博士及張海超博士；非執行董事魏義良先生、周可祥博士及張蕾娣 女士；獨立非執行董事華風茂先生、喻長遠博士及梁曉燕女士。 百奥赛图（北京）医药科技股份有限公司 首次公开发行股票科 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 海外監管公告 本公告乃百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條的規定刊發。茲載列本公司於上海證券交易所 網站刊發的《首次公開發行股票科創板上市公告書》，僅供參閱。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 百奧賽圖（北京）醫藥科技股份有限公司 董事長、首席執行官兼執行董事 沈月雷 香港，2025年12月9日 於本公告日期，本公司董事會包括董事長、首席執行官兼執行董事沈月雷博士、 執行董事倪健博士及張海超博士；非執行董事魏義良先生、周可祥博士及張蕾娣 女士；獨立非執行董事華風茂先生、喻長遠博士及梁曉燕女士。 股票简称：百奥赛图 股票代码：688796 百奥赛图（北京）医药科 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、完整、及时，没有虚假记 载、误导性陈述或重大遗漏。 经上海证券交易所审核同意，百奥赛图（北京）医药科技股份有限公司（以下简称"本公司"、"百奥赛 图"或"发行人"）发行的人民币普通股股票将于2025年12月10日在上海证券交易所科创板上市，上市公 告书全文和首次公开发行股票的招股说明书在上海证券交易所网站（http://www.sse.com.cn/）和符合中 国证监会规定条件网站（中国证券网，网址www.cnstock.com；中证网，网址www.cs.com.cn；证券时报 网，网址www.stcn.com；证券日报网，网址www.zqrb.cn；经济参考网，网址www.jjckb.cn；中国金融新 闻网，网址www.financialnews.com.cn；中国日报网，网址cn.chinadaily.com.cn）披露，并置备于发行 人、上交所、本次发行保荐人（主承销商）中国国际金融股份有限公司的住所，供公众查阅。 一、上市概况 （四）本次公开发行后的总股本：446,898,420股 （五 ...

智通财经APP讯，百奥赛图(688796.SH)公告，公司股票将于2025年12月10日在上海证券交易所科创板 上市。 ...

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

【#港股公司回A提速# A+H演绎"双向奔赴"】随着资本市场互联互通机制的持续完善，A股与港股之 间"双向奔赴"的上市热潮正以前所未有的活力席卷市场。港股生物科技企业百奥赛图即将登陆科创板， 成为2025年两地资本市场双向互动的又一标志性事件。从港股公司"返乡"回A，到A股企业"出海"赴 港，再到子公司分拆上市的跨市场布局，A+H上市生态正不断丰富，不仅为企业开辟了多元化融资渠 道，更推动内地与香港资本市场在资源配置、制度创新等层面实现深度融合。（证券时报） 来源：新浪科技 ...

近日，临床前CRO企业百奥赛图正式登陆上交所科创板，引发市场关注。公司凭借"千鼠万抗"计划与 RenMice全人抗体平台，在生物医药领域具有一定技术积累与业务布局。然而，其招股书及财务数据背 后，却透露出盈利依赖研发压缩、关联交易占比高、专利侵权诉讼、未弥补亏损巨大等多重风险，值得 投资者警惕。 一、扭亏为盈背后的"成本压缩术"：研发投入大幅缩水 从财务表现看，百奥赛图在2022年至2024年间营业收入稳步增长，归母净利润从-6.02亿元转为正收益 3354.18万元，今年前三季度更是实现1.14亿元净利润，看似走出亏损泥潭。 然而，仔细观察发现，公司同期研发费用从6.99亿元骤降至3.24亿元，研发人员总数从627人减至337 人，专职研发人员更是从58人锐减至5人。2022至2024年间，公司营收增长4.46亿元，研发费用却下降 3.75亿元。这引发市场质疑：盈利改善是否更多来自"节流"而非真正的业务成长？公司解释称"大规模 研发阶段已结束"，但作为一家以技术为核心竞争力的生物医药企业，研发投入的持续性仍是其长期价 值的关键。 二、关联交易与专利诉讼双重隐患 抗体开发业务是百奥赛图的重要增长点，2022至 ...

Core Viewpoint - The approval of the IND for IDEAYA's dual-target ADC project IDE034 by the FDA marks a significant advancement in the development of innovative cancer therapies, potentially enhancing the company's market position and investor interest [1][2]. Group 1: Company Developments - 百奥赛图-B's stock rose over 3%, reaching 31.86 HKD with a trading volume of 12.99 million HKD following the announcement of FDA IND approval for IDEAYA's IDE034 project [1]. - IDEAYA Biosciences, Inc. plans to initiate patient enrollment for the Phase I clinical trial in Q1 2026, focusing on solid tumors co-expressing B7H3 and PTK7, including lung cancer, colorectal cancer, head and neck cancer, and ovarian/gynecological tumors [1]. Group 2: Clinical Research Insights - Preclinical studies indicate that IDE034 demonstrates deep and durable tumor regression in various B7H3/PTK7 positive tumor models, showcasing strong anti-tumor activity [2]. - IDEAYA intends to explore a combination therapy strategy with its PARG inhibitor IDE161 to enhance the durability of treatment effects, with plans to present additional data on the combined treatment mechanism at a major medical conference in H1 2026 [2]. - The co-expression rates of B7H3/PTK7 in solid tumors are approximately 30% in lung cancer, 46% in colorectal cancer, and 27% in head and neck cancer, indicating broad clinical applicability [2].

Core Viewpoint - The stock of Baiaosaitu-B (02315) has seen an increase of over 3%, currently trading at 31.86 HKD, following the announcement of FDA approval for a clinical trial by its partner IDEAYA Biosciences, Inc. for a novel dual-targeting antibody-drug conjugate project [1][2]. Group 1: Company Developments - IDEAYA Biosciences has received FDA approval for its Investigational New Drug (IND) application to advance the Phase I clinical trial of the B7H3/PTK7 dual-specific antibody-drug conjugate (ADC) [1]. - The patient enrollment for the trial is expected to begin in Q1 2026, focusing on solid tumors co-expressing B7H3 and PTK7, including lung cancer, colorectal cancer, head and neck cancer, and ovarian/gynecological tumors [1][2]. Group 2: Clinical Research Insights - Preclinical studies indicate that IDE034 monotherapy shows deep and durable tumor shrinkage in various B7H3/PTK7 positive tumor models, demonstrating strong anti-tumor activity [2]. - IDEAYA plans to explore a combination treatment strategy of IDE034 with its PARG inhibitor IDE161 to enhance the durability of efficacy, with data supporting the combination treatment mechanism to be shared at a major medical conference in H1 2026 [2]. - The co-expression rates of B7H3/PTK7 in solid tumors are approximately 30% for lung cancer, 46% for colorectal cancer, and 27% for head and neck cancer, indicating broad clinical applicability [2].

Core Insights - IDEAYA Biosciences has received IND approval from the FDA for its first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC) project, IDE034, marking a significant milestone in its clinical development [1][2] Group 1: Clinical Development - The Phase I clinical trial for IDE034 is expected to begin patient enrollment in Q1 2026, targeting solid tumors co-expressing B7H3 and PTK7, including lung cancer, colorectal cancer, head and neck cancer, and ovarian/gynecological tumors [1] - Preclinical studies have shown that IDE034 monotherapy exhibits deep and durable tumor shrinkage in various B7H3/PTK7 positive tumor models, indicating strong anti-tumor activity [2] Group 2: Technological Advancements - The IND approval validates IDEAYA's RenLite platform and proprietary linker-payload technology, showcasing its leading capabilities in the discovery and optimization of bispecific ADCs [2] - The company plans to explore combination therapy strategies with its PARG inhibitor, IDE161, to enhance the durability of treatment effects [2] Group 3: Market Potential - The co-expression rates of B7H3 and PTK7 in solid tumors are approximately 30% in lung cancer, 46% in colorectal cancer, and 27% in head and neck cancer, highlighting the broad clinical applicability of IDE034 [2] - The company aims to provide high-quality source molecules to partners and actively seek external licensing opportunities for early-stage assets [2]